Riskpilot← Back to searchSign inGet full accessTHERACULE AS
ASActiveOrg 921692250Oslo Science Park Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20181 employees
Revenue 2022
NOK 0
EBITDA margin
—
-418% vs 2021
Equity ratio
-21.0%
Financial strength
Net profit 2022
NOK -1,8M
-254% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -1,6M | -418% |
| Net profit | NOK -1,8M | -254% |
| Total assets | NOK 9,1M | +17% |
| Equity | NOK -1,9M | -1835% |
| Employees | 1 | — |
Legal name
THERACULE AS
Org number
921692250
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. november 2018
Share capital
NOK 38 010
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Bioteknologi og andre produkter og tjenester som naturlig hører sammen med dette herunder å delta i andre selskaper med lignende virksomhet, samt investeringer i aksjer, eiendom og andre verdiformål.
Address
Oslo Science Park Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −334 | −552 | −52 | −578 |
| EBITDA | 0 | −538 | −943 | −316 | −1 637 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −538 | −943 | −316 | −1 637 |
| Net financials | 0 | −5 | −331 | −194 | −167 |
| Profit before tax | 0 | −543 | −1 274 | −510 | −1 804 |
| Tax | 0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −543 | −1 274 | −510 | −1 804 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 30 | 1 554 | 7 887 | 7 703 | 9 051 |
| Equity | 30 | −513 | −1 786 | −98 | −1 903 |
| Long-term debt | 0 | 0 | 0 | 0 | 3 620 |
| Short-term debt | 0 | 2 067 | 9 673 | 7 801 | 7 334 |
| Total debt | 0 | 2 067 | 9 673 | 7 801 | 10 953 |
EBITDA margin
-163734000.0%
This company
15.8%
Market median
-1036291239% vs market
20182022
Equity ratio
-21.0%
This company
38.2%
Market median
-155% vs market
20182022
Return on equity
-180439500.0%
This company
18.4%
Market median
-980649557% vs market
20182022
Net profit margin
-180439500.0%
This company
8.1%
Market median
-2227648248% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
5.76×
This company
0.62×
Market median
-829% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 40.41% | 40.41% | 2022 | |
| Individual | 31.18% | 31.18% | 2022 | |
| Individual | 22.49% | 22.49% | 2022 | |
| Individual | 3.95% | 3.95% | 2022 | |
Yannick Quesnel | Company | 1.97% | 1.97% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Mermaid Bioventures As
THERACULE AS Board members of THERACULE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Engelmann | Board of Directors | 0 companies |
| Alexander Dettmar Crawford | Chairman | 0 companies |